Keytruda Conditionally Approved in US for Primary Mediastinal B-cell Lymphoma
News
The U.S. Food and Drug Administration has granted accelerated approval to Keytruda (pembrolizumab) for the treatment of relapsed or refractory primary mediastinal large B-cell lymphoma (PMBCL), making it the first anti-PD-1 therapy ... Read more